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Background: Resuscitation at birth with 100% oxygen is known to increase the oxidative burden with concomitant
deleterious effects. Although fractions of inspired oxygen (FiO2)< 100% are widely used in preterm infants, starting
resuscitation at a (too) low FiO2 may result in hypoxia. The objective of this study is to compare the safety and
efficacy of resuscitating very preterm infants with an initial FiO2 of 30% versus 65%.
Methods/design: In this double-blind, randomized controlled trial, 200 very preterm infants with a gestational
age< 32 weeks will be randomized to start resuscitation after birth with either 30% or 65% oxygen. The FiO2 will
be adjusted based on oxygen saturation measured by pulse oximetry (SpO2) and pulse rate (which should be over
100 beats per minute) in order to achieve a target SpO2 of 88–94% at 10 min of life. The FiO2 and pulse oximetry
data will be continuously recorded.
The primary outcome is survival without bronchopulmonary dysplasia, as assessed by a physiological test at 36 weeks
postmenstrual age. The secondary outcomes include the time to achieve SpO2> 88%, Apgar score at 5 min,
cumulative O2 exposure, oxidative stress (as determined by glutathione synthesis and oxidative stress markers),
retinopathy of prematurity, brain injury and neurodevelopmental outcome at 2 years of age.
This study will provide insight into determining the appropriate initial FiO2 to start resuscitation of very preterm infants.
Trial registration: www.trialregister.nl, NTR243.
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Resuscitating the newborn at birth with 100% oxygen is
known to increase the oxidative burden with concomi-
tant deleterious effects [1]. The latest International
Liaison Committee on Resuscitation (ILCOR) guidelines
recommend that “for babies born at term it is best to
begin resuscitation with air rather than 100% oxygen”
and that “administration of supplementary oxygen
should be guided by oximetry” [2]. However, for preterm
infants, the optimal fraction of inspired oxygen (FiO2) to
start resuscitation is still unknown. The ILCOR states* Correspondence: h.vangoudoever@amc.uva.nl
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reproduction in any medium, provided the orthat “blended oxygen and air may be given judiciously”
and “both hyperoxemia and hypoxemia” should be
avoided [2].
Several small studies on FiO2 for resuscitating preterm
infants have been performed. Wang et al. compared the
use of initiating the resuscitation of preterm infants with
either room air (n=18) or 100% oxygen (n=23) [3]. All
infants in the room air group required an increase of the
FiO2 to achieve the targeted oxygen saturation (SpO2),
and the authors recommended that room air should not
be used for resuscitating preterm infants. Escrig et al.
compared initiating resuscitation of preterm infants with a
gestational age (GA)≤ 28 weeks with either 30% or 90%
oxygen [4]. In this study, the FiO2 in the low-
oxygen group (n= 19) was increased stepwise to 45%, and
the FiO2 in the high-oxygen group (n=23) was reduced tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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et al., resuscitation with 30% oxygen (n=37) resulted in
decreased oxidative stress markers and a decreased risk of
bronchopulmonary dysplasia (BPD) compared to starting
resuscitation with 90% (n=41) [5]. Also in this study, FiO2
in both groups was increased stepwise in the low-oxygen
group and decreased in the high-oxygen group, reaching
55% at 5 min in both groups.
From these data, it can be concluded that initiating
the resuscitation of preterm infants with room air is too
low, while starting with 90% FiO2 is too high. Because it
is important to avoid both hypoxia and hyperoxia, the
optimal initial FiO2 for resuscitating preterm infants
needs to be determined. Therefore, we hypothesize that
resuscitation of very preterm infants (GA< 32 weeks)
with an initial FiO2 of 30% is safe, decreases oxidative
stress and improves outcome compared to resuscitation
with an initial FiO2 of 65%.
Methods/design
Trial design
The study is a double-blind, randomized controlled trial
and will be performed in the Neonatal Intensive Care
Unit (NICU) of the Erasmus MC - Sophia Children’s
Hospital, Rotterdam, The Netherlands. The study is
investigator-initiated, without funding from the pharma-
ceutical industry. The study protocol has been approved
by the Erasmus MC Medical Ethics Committee. Serious
adverse events (death, retinopathy of prematurity
(ROP) ≥ grade 3 and intraventricular hemorrhage
(IVH) ≥ grade 3) will be reported to the medical ethics
committee, which will monitor the study safety.
Subjects
The inclusion criteria are infants with a GA< 32 weeks
born at the Erasmus MC-Sophia Children’s Hospital.
Assessment of the GA will be based on early fetal ultra-
sonography or on the date of the last menstrual period.
The exclusion criteria are any known major congenital
malformations, chromosome defects, or metabolic,
endocrine or renal disorders.
Because this study involves an acute intervention at
birth, written informed consent will be obtained ante-
natally. All mothers admitted to Erasmus MC-Sophia
Children’s Hospital at risk for preterm delivery before 32
weeks of gestation (e.g., premature labor, preeclampsia,
intrauterine growth retardation) will be approached for par-
ticipation in the study. When parents have consented to
participate in the study and there has been an actual pre-
term delivery, the preterm infant will be included at birth.
Research setting and randomization
The Erasmus MC-Sophia Children’s Hospital has six
resuscitation units, which have been modified for thisstudy by adding an additional oxygen blender
(PM5200, Precision Medical Inc., Northampton, PA,
USA) (Figure 1). This additional oxygen blender is
not visible to the physician and will be randomized
after each inclusion to either 30% or 65% oxygen
using a computer-generated list.
When an infant with prenatal consent is born, the
physician will activate the research setting by activa-
tion of a switch just before delivery. By activating
this research switch, the regular oxygen blender (Bird
Ultrablender, Cardinal Health, Dublin, OH, USA) will
be connected to the additional oxygen blender.
Administered oxygen will come from the additional
oxygen blender, randomized to 30% or 65% oxygen,
and thus resuscitation will be started with either 30%
or 65% oxygen.
Resuscitation
All resuscitations of preterm infants are performed by
a neonatologist or an experienced neonatologist in
training. Immediately after cord clamping, the infant
will be placed on the resuscitation unit. The resusci-
tation is performed according to standard guidelines,
i.e., the infant is stimulated and heat loss is pre-
vented. A disposable SpO2 sensor (Nellcor Max-N,
Covidien, Dublin, Ireland) will be applied to the right
hand or wrist before switching on the pulse oximeter
(Nellcor OxiMax N-600x, Covidien, Dublin, Ireland).
Infants will be resuscitated with either a flow inflating
mask (Jackson Reese modification T-piece system
breathing system, Intersurgical, Wokingham, UK) or a
T-piece resuscitator (Neopuff, Fisher & Paykel Healthcare,
Auckland, New Zealand), according to the physician’s
preferences.
Resuscitation is started with either 30% or 65%
oxygen, for which the physician will be blinded. The
objective of the resuscitation is to achieve a target
SpO2 of 88–94% at 10 min after birth. If the pulse
rate remains stable and over 100 beats per minute
(bpm), no adjustment of FiO2 is advised. At all times,
the physician can adjust the FiO2 if the clinical situ-
ation is not satisfactory (e.g., persistent bradycardia or
SpO2 >94%). To adjust the FiO2, the physician deac-
tivates the research switch by which the additional
oxygen blender is deactivated, and the administered
FiO2 is supplied via the regular oxygen blender. The
FiO2 can then be manually adjusted to the desired
FiO2, without the physician being aware of the initial
FiO2 to which the infant was randomized.
Outcome parameters
Primary outcome
Survival without BPD at 36 weeks postmenstrual age
(PMA).
Figure 1 Adjusted resuscitation unit. Dotted lines depict the adjustments made to the resuscitation unit. The blinded oxygen blender is randomized
to administer either 30% or 65% oxygen. The OR port depicts the switch by which the research setting can be activated or deactivated.
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1. Resuscitation: Apgar score at 5 min, time after birth
to achieve SpO2> 88% and cumulative O2 exposure
during resuscitation.
2. Oxidative stress: Glutathione (GSH) synthesis and
oxidative stress markers
3. Incidence of ROP and brain injury.
4. Neurodevelopmental outcome at 2 years of age.
The timeline of the study design is depicted in Figure 2.
Collection resuscitation data
Medical record documentation often varies from ac-
tual interventions, especially in acute situations [6].
Therefore, video recordings will be made to analyze
resuscitation with regard to time of birth and the
timeline of the resuscitation (e.g., time to start SaO2
recording, time to start respiratory support and the
time to intubation, when applicable). The time of
birth is defined as the time of cord clamping. The
FiO2 will be continuously recorded (1 Hz) using a
medical oxygen monitor (MX300 Medical Oxygen
Monitor, Teledyne, City of Industry, CA, USA). The




Two definitions for the diagnosis of BPD will be used. First,
the definition of BPD for preterm infants with a GA< 32
weeks described by Jobe et al. will be used (Table 1) [7].
According to this definition, BPD is present when an infant
is treated with FiO2> 21% for at least 28 days and is further
classified according to the need for oxygen and/or respira-
tory support at 36 weeks PMA.
Second, the diagnosis of BPD will be assessed at 36
weeks PMA based on the physiological criteria of Walsh
et al. [8]. Infants treated with mechanical ventilation or
continuous positive airway pressure (CPAP), or infants re-
ceiving FiO2≥ 30% oxygen with oxygen saturations< 96%
are diagnosed with BPD. For infants receiving< 30%
oxygen or infants receiving≥ 30% oxygen with oxygen
saturations> 96%, a timed oxygen reduction test will be
performed as described by Walsh et al. [8]. During the
timed oxygen reduction test, BPD is diagnosed when
oxygen saturations are< 90% for more than 5 consecutive
min or< 80% for more than 15 s. No BPD is defined as
oxygen saturations≥ 90% during weaning to room air.pulmonary dysplasia.
Table 1 Criteria for bronchopulmonary dysplasia for
preterm infants with a gestational age< 32 weeks
Treatment with oxygen >21% for at least 28 days plus
Mild BPD Breathing room air at 36 weeks PMA
Moderate BPD Need for< 30% oxygen at 36 weeks PMA
Severe BPD Need for≥ 30% oxygen and/or positive pressure at
36 weeks PMA
Adapted from Jobe et al. [7]. BPD=bronchopulmonary dysplasia,
PMA=postmenstrual age. A day of treatment with oxygen> 21% means that
the infant received oxygen> 21% for more than 12 h on that day.
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As part of standard care, ROP will be assessed at a post-
natal age of 5 weeks by a pediatric ophthalmologist.
ROP will be diagnosed and classified according to the
International Classification of Retinopathy of Prematurity
(ICROP) [9].
Brain injury
Substantial brain injury will be diagnosed according to the
definition previously described in the EUNO trial [10], i.e.,
grade 3 or 4 IVH [11] or periventricular leukomalacia based
on ultrasound images and/or MRI of the brain [12].
Neurodevelopmental outcome
As part of standard care, all preterm infants born with a
GA< 32 weeks will be followed until 2 years of age. At 2
years, certified neurodevelopmental physiologists will
evaluate the infants using the Bayley Scales of Infant
Development, 3rd Edition (BSID III).
Glutathione concentration and synthesis rates
Tracer infusion protocol and blood sampling
On the 2nd postnatal day, a primed (20 μmolkg−1) con-
tinuous (20 μmolkg−1d−1) infusion of [U-13 C]glycine
(99% enriched, Cambridge Isotope Laboratories, Andover,
MA, USA; sterility and pyrogenicity tested) will be admi-
nistered for 8 h using a Perfusor fm infusion pump (B|
Braun Medical B.V., Oss, The Netherlands). Blood will be
sampled from an indwelling arterial catheter after 6, 7 and
8 h, and collected in EDTA-containing microtainers. After
centrifugation at 3,500× g for 10 min, the plasma fraction
will be removed, and the lower layer (containing primarily
erythrocytes) will be reconstituted to its original volume
with ice-cold distilled water. To calculate the fractional
synthesis rates (FSR) and absolute synthesis rates (ASR) of
GSH, concentration and enrichment of GSH and its
precursor glycine will be determined in the erythrocytes.
Glutathione enrichment and concentration
Analysis of GSH will be performed on a LC-Isolink
interface coupled to a Delta XP isotope ratio mass spec-
trometer (LC-IRMS) (Thermo Fisher, Bremen, Germany)using a recently developed method [13]. This highly sen-
sitive method requires only a very small sample and does
not require derivatization of the sample.
Glycine enrichments
The erythrocyte enrichment of 13C glycine will be mea-
sured by gas chromatography-mass spectrometry
(GCMS) as its ethyl chloroformate (ECF) ester deriva-
tives, using a MSD 5975 C Agilent GCMS (Agilent
Technologies, Amstelveen, The Netherlands). Briefly,
25-μl aliquots of the remaining supernatant used for the
GSH analysis will be acidified by adding 50 μl of 0.1 M
HCl and diluted with 125 μl of distilled water. ECF deri-
vatization of the samples will be performed according to
a modified procedure of Hušek [14]. A CP-Sil 17 column
(25 m×0.25 mm id, 0.12-μm film thickness; Varian,
Middelburg, The Netherlands) will be used for the
separation. The samples will be measured using a selected
ion monitoring mode (SIM) method. The mass fragments
with a mass to charge (m/z) of 102.1 for unenriched
(M)and an m/z 103.1 for the enriched (M+1) glycine,
respectively, have been selected for this purpose.
Calculations
The FSRGSH represents the fraction of the total intraery-
throcytic GSH pool that is renewed per unit of time and is
expressed as %/d.
FSRGSH %=dð Þ ¼
slope E U13C½ GSHt6;7;8
Eintraerythrocytic U13C½ glycine
 24h 100%;
where E stands for the enrichment expressed as MPE. The
nominator (product) of this equation represents the
hourly increase in [U-13 C]glycine bound to GSH, as
calculated from the increase in enrichment between 6 and
8 h of infusion. The denominator (precursor) represents
the intraerythrocytic U-13 C enrichment of free glycine at
isotopic steady state.
Subsequently, the intravascular ASRGSH, which repre-
sents the absolute amount of GSH that is produced per
unit of time (mg/(kgday)), can be calculated using the
following equation:
ASRGSHðmg= kg dð Þ
¼ FSRGSH= 100 conc: 307 ht 0:075ð Þ
where conc. is GSH concentration in mmol/l packed
erythrocytes, 307 is the molecular weight of GSH, ht is
hematocrit, and 0.075 is the estimated circulating
volume in a preterm neonate, expressed as l/kg.
Oxidative stress markers
Oxidative stress markers in plasma and urine will be
determined within 24 h of birth, on postnatal day 6 and
on postnatal day 28.
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Blood samples, drawn from an arterial catheter or via a
heel prick, will be collected in heparinized microtainers
and immediately placed on melting ice. After centrifugation
at 3,500× g for 10 min, the plasma fraction will be removed
from the lower layer and stored at −80 °C until further
analysis. Plasma samples will be shipped on dry ice to the
University of Siena (Siena, Italy), where the NPBI will be
determined according to previously described methods
[15].
Isoprostanes and 8-hydroxy-2’-deoxyguanosine (8-oxo-dG)
Urine will be collected by placing gauze in the infants’
diapers. After centrifugation at 2,800 × g for 5 min, the
urine will be stored at −80 °C until further analysis.
Urine samples will be shipped on dry ice to the University
Hospital LA Fe (Valencia, Spain), where the urinary
isoprostane and 8-oxo-dG will be determined according to
previously described methods [16].
Statistical analysis
Power calculation based on the incidence of BPD shows
that, with an incidence of 30% and an expected reduc-
tion of 15%, 100 infants per group will be needed to find
a statistically significant difference with an α of 0.05 and
a power of 0.80. Differences between groups will be
assessed using the Mann-Whitney test for continuous
measurements and the chi-square test for categorical
measurements (p< 0.05).
Discussion
Although this study concerns the acute intervention of
neonatal resuscitation, the randomization and blinding
are optimal in this study design. Because cases of acute
preterm delivery will not be included in this study, the
main limitation will be the selection bias. Since informed
consent will be obtained before birth, only mothers who
are actually hospitalized antenatally will be approached
by the researchers. Consequently, all included infants
will have received at least one dose of prenatal steroids.
As prenatal steroids have proven to be beneficial to
immature lungs, included infants will likely have fewer
respiratory difficulties than the acute cases. Furthermore,
administration of prenatal steroids is associated with
increased antioxidant enzyme activity, which reduces
susceptibility to hypoxia and to oxidative damage as a
result of hyperoxia [17]. In short, the studied cases may
show less morbidity such as BPD than the total popula-
tion of very preterm infants.
The selection bias could be circumvented by a waiver of
informed consent. In 1996, the Food and Drug Adminis-
tration (FDA) and the Department of Health and Human
Services (DHHS) published guidelines on exceptions from
the informed consent requirements in specific situations[18]. For emergency research, these guidelines stipulate
that the institutional review board (IRB) may approve a
clinical investigation without requiring informed consent
from all research subjects after meeting certain criteria.
These criteria include informed consent not being feasible
because the intervention must be performed before con-
sent from the subjects’ legally authorized representative
can be obtained, as would be the case in this study when
preterm infants are born acutely. Because informed con-
sent can be sought in a sufficient number of very preterm
deliveries, we decided that it would not be ethical to use a
waiver of informed consent.
This study is performed in an affluent health care
setting, and blended oxygen might not be available in all
hospitals. However, according to international guide-
lines, preterm infants should be born in a tertiary
hospital whenever possible, and, in Western countries,
most very preterm infants are indeed born within a
tertiary hospital. Since it has been shown that room air
and 100% oxygen are both not ideal in the resuscitation
of preterm infants, it is important to study the optimal
FiO2 to start resuscitation of these infants.
Trial status
The trial is currently enrolling patients. We expect to
finish patient recruitment in March 2012 and present
the results over the course of 2012.
Abbreviations
FiO2: fraction of inspired oxygen; SpO2: oxygen saturation; GA: gestational
age; BPD: bronchopulmonary dysplasia; PMA: postmenstrual age;
GSH: glutathione.
Competing interests
The authors declare that there are no competing interests
Acknowledgements
The authors would like to thank Arie Koedood for his assistance with the
technical design of the study. Additionally, we would like to thank the
medical staff for performing the resuscitations according to the study
protocol. Finally, we would like to thank the Department of Obstetrics for
performing the study on their ward.
Author details
1Department of Pediatrics, Division of Neonatology, Erasmus Medical Center -
Sophia Children’s Hospital, Rotterdam, The Netherlands. 2Department of
BioMechanical Engineering, Faculty of Mechanical, Maritime & Materials
Engineering, Delft University of Technology, Delft, The Netherlands.
3Department of Pediatrics, Obstetrics and Reproductive Medicine, University of
Siena, Siena, Italy. 4Department of Pediatrics, Division of Neonatology, University
Children’s Hospital La Fe, Valencia, Spain. 5Department of Pediatrics, Emma
Children’s Hospital - AMC, Amsterdam, The Netherlands. 6Department of
Pediatrics, VU University Medical Center, Amsterdam, The Netherlands.
Authors’ contribution
DR: study design, acquisition of data, analysis and interpretation of data,
drafting and revising the manuscript. HS, ML, GB, MV: analysis and
interpretation of data, revising the manuscript. AvdE: technical support for
design and data acquisition, revising the manuscript. JvG: conception and
study design, interpretation of data, revising the manuscript. MJV:
conception and study design, interpretation of data, revising the manuscript.
All authors have read and approved the final manuscript.
Rook et al. Trials 2012, 13:65 Page 6 of 6
http://www.trialsjournal.com/content/13/1/65Received: 24 October 2011 Accepted: 23 May 2012
Published: 23 May 2012
References
1. Saugstad OD, Ramji S, Soll RF, Vento M: Resuscitation of Newborn Infants
with 21 % or 100 % Oxygen: An Updated Systematic Review and
Meta-Analysis. Neonatology 2008, 94:176–182.
2. Perlman JM, Wyllie J, Kattwinkel J, Atkins DL, Chameides L, Goldsmith JP,
Guinsburg R, Hazinski MF, Morley C, Richmond S, et al: Part 11: neonatal
resuscitation: 2010 International Consensus on Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care Science With
Treatment Recommendations. Circulation 2010, 122:S516–S538.
3. Wang CL, Anderson C, Leone TA, Rich W, Govindaswami B, Finer NN:
Resuscitation of preterm neonates by using room air or 100 % oxygen.
Pediatrics 2008, 121:1083–1089.
4. Escrig R, Arruza L, Izquierdo I, Villar G, Saenz P, Gimeno A, Moro M, Vento M:
Achievement of targeted saturation values in extremely low gestational
age neonates resuscitated with low or high oxygen concentrations: a
prospective, randomized trial. Pediatrics 2008, 121:875–881.
5. Vento M, Moro M, Escrig R, Arruza L, Villar G, Izquierdo I, Roberts LJ 2nd,
Arduini A, Escobar JJ, Sastre J, Asensi MA: Preterm Resuscitation With Low
Oxygen Causes Less Oxidative Stress, Inflammation, and Chronic Lung
Disease. Pediatrics 2009, 124:e439–e449.
6. Rich WD, Leone T, Finer NN: Delivery room intervention: improving the
outcome. Clin Perinatol 2010, 37:189–202.
7. Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care
Med 2001, 163:1723–1729.
8. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R,
Peters N, Miller N, Muran G, et al: Impact of a physiologic definition on
bronchopulmonary dysplasia rates. Pediatrics 2004, 114:1305–1311.
9. The International Classification of Retinopathy of Prematurity revisited.
Arch Ophthalmol 2005, 123:991–999.
10. Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D,
Greenough A, Van Overmeire B, Jonsson B, Hallman M, Baldassarre J:
Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in
premature babies (EUNO): a randomised controlled trial. Lancet 2010,
376:346–354.
11. Papile LA, Burstein J, Burstein R, Koffler H: Incidence and evolution of
subependymal and intraventricular hemorrhage: a study of infants with
birth weights less than 1,500 gm. J Pediatr 1978, 92:529–534.
12. De Vries LS, Regev R, Pennock JM, Wigglesworth JS, Dubowitz LM:
Ultrasound evolution and later outcome of infants with periventricular
densities. Early Hum Dev 1988, 16:225–233.
13. Schierbeek H, Te Braake F, Godin JP, Fay LB, van Goudoever JB: Novel
method for measurement of glutathione kinetics in neonates using
liquid chromatography coupled to isotope ratio mass spectrometry.
Rapid Commun Mass Spectrom 2007, 21:2805–2812.
14. Husek P: Rapid derivatization and gas chromatographic determination of
amino acids. J Chromatogr 1991, 552:289–299.
15. Paffetti P, Perrone S, Longini M, Ferrari A, Tanganelli D, Marzocchi B,
Buonocore G: Non-protein-bound iron detection in small samples of
biological fluids and tissues. Biol Trace Elem Res 2006, 112:221–232.
16. Milne GL, Sanchez SC, Musiek ES, Morrow JD: Quantification of F2-
isoprostanes as a biomarker of oxidative stress. Nat Protoc 2007,
2:221–226.
17. Vento M, Aguar M, Escobar JJ, Arduini A, Escrig R, Brugada M, Izquierdo I,
Asensi MA, Sastre J, Saenz P, Gimeno A: Antenatal Steroids and
Antioxidant Enzyme Activity in Preterm Infants: Influence of Gender and
Timing. Antioxid Redox Signal 2009, 11(12):2945–2955.
18. Protection of human subjects. http://www.access.gpo.gov/nara/cfr/
waisidx_02/21cfr50_02.html.
doi:10.1186/1745-6215-13-65
Cite this article as: Rook et al.: Resuscitation of very preterm infants
with 30% vs. 65% oxygen at birth: study protocol for a randomized
controlled trial. Trials 2012 13:65.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
